SCM Lifescience Co. Ltd
SCM Lifescience Co., Ltd. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was founded in 2014 and is headquartered in Incheon, South Korea.
SCM Lifescience Co. Ltd (298060) - Total Liabilities
Latest total liabilities as of September 2025: ₩13.70 Billion KRW
Based on the latest financial reports, SCM Lifescience Co. Ltd (298060) has total liabilities worth ₩13.70 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SCM Lifescience Co. Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how SCM Lifescience Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SCM Lifescience Co. Ltd Competitors by Total Liabilities
The table below lists competitors of SCM Lifescience Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
415380
KQ:415380
|
Korea | ₩11.20 Billion |
|
Suvidhaa Infoserve Limited
NSE:SUVIDHAA
|
India | ₹355.20 Million |
|
Triangle Energy (Global) Ltd
AU:TEG
|
Australia | AU$20.39 Million |
|
Innelec Multimedia
PA:ALINN
|
France | €62.68 Million |
|
Famous Brands Ltd
JSE:FBR
|
South Africa | ZAC2.47 Billion |
|
Euromax Resources Ltd
PINK:EOXFF
|
USA | $50.33 Million |
|
LITHIA MTRS
BE:LMO
|
Germany | €16.63 Billion |
|
Saint Jean Carbon Inc
OTCQB:TORVF
|
USA | $1.85 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down SCM Lifescience Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SCM Lifescience Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SCM Lifescience Co. Ltd (2017–2024)
The table below shows the annual total liabilities of SCM Lifescience Co. Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩8.99 Billion | +82.36% |
| 2023-12-31 | ₩4.93 Billion | -42.06% |
| 2022-12-31 | ₩8.51 Billion | -9.79% |
| 2021-12-31 | ₩9.43 Billion | -28.61% |
| 2020-12-31 | ₩13.21 Billion | -45.37% |
| 2019-12-31 | ₩24.19 Billion | -72.66% |
| 2018-12-31 | ₩88.46 Billion | +485.43% |
| 2017-12-31 | ₩15.11 Billion | -- |